IMV

IMV Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
+0.100
+3.39%
Opening 10:03 07/13 EDT
OPEN
3.000
PREV CLOSE
2.950
HIGH
3.080
LOW
2.960
VOLUME
35.97K
TURNOVER
--
52 WEEK HIGH
5.12
52 WEEK LOW
1.350
MARKET CAP
188.20M
P/E (TTM)
-7.0520
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMV stock price target is 7.44 with a high estimate of 13.00 and a low estimate of 2.999.

EPS

IMV News

More
IMV maintains the remainder of its At-the-Market Facility under its new Base Shelf Prospectus
Business Wire · 06/30 22:05
IMV Announces Annual and Special Meeting of Shareholders Voting Results
Business Wire · 06/29 22:05
IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus
Business Wire · 06/19 21:26
IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting
Business Wire · 06/15 12:05
IMV to Present at Raymond James' Human Health Innovation Conference
Business Wire · 06/08 12:05
Penny Stocks to Buy Using Technical Analysis for June 2020
These low-priced stocks may prove exempt from a potential downtrend based on their bullish technical signals.
Investopedia · 05/29 16:14
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
Business Wire · 05/29 13:05
IMV's DPX-Survivac study shows prolonged durable clinical responses
Seeking Alpha - Article · 05/29 12:49

Industry

Biotechnology & Medical Research
+0.86%
Pharmaceuticals & Medical Research
+1.14%

Hot Stocks

Symbol
Price
%Change

About IMV

IMV Inc. is a clinical-stage biopharmaceutical company focused on immunotherapy in oncology. The Company’s drug delivery platform (DPX) enables the programming of immune cells in vivo. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is a monotherapy in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications.
More

Webull offers kinds of Imv Inc stock information, including NASDAQ:IMV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMV stock methods without spending real money on the virtual paper trading platform.